dabigatran etexilate: clinical use

Prescribing considerations

• Confirm a licensed indication and assess thromboembolic benefit against bleeding risk.
• Calculate creatinine clearance using Cockcroft–Gault before treatment; reassess if renal function may decline.
• Review age, body weight, gastrointestinal disease, hepatic function, interacting medicines and adherence.
• Plan interruption around invasive procedures according to renal function, bleeding risk and procedural urgency.
• Ensure patients understand bleeding precautions, missed-dose instructions, capsule handling and the need to carry anticoagulant identification.

Contraindications and cautions

• Active clinically significant bleeding or a lesion or condition carrying a significant risk of major bleeding.
• Severe renal impairment in adults; the paediatric renal threshold differs and is formulation-specific.
• Concomitant anticoagulation except in specified switching, catheter or ablation circumstances.
• Hepatic impairment or liver disease expected to affect survival.
• Specified strong P-glycoprotein inhibitors, including systemic ketoconazole, itraconazole, ciclosporin, dronedarone and glecaprevir/pibrentasvir.
• Prosthetic heart valves requiring anticoagulation.
• Hypersensitivity to the active substance or excipients.

Monitoring

• Before treatment: full blood count, liver function, urea and electrolytes, serum creatinine with calculated creatinine clearance, body weight and baseline clotting screen.
• During treatment: periodically review renal and hepatic function, full blood count, adherence, bleeding, thrombosis and interacting medicines; monitor more often with frailty, older age, renal impairment or intercurrent illness.
• Routine INR monitoring is inappropriate. In selected urgent or high-exposure situations, diluted thrombin time, ecarin clotting time or activated partial thromboplastin time may assist interpretation.
• Investigate unexplained falls in haemoglobin, haematocrit or blood pressure for occult bleeding.

Clinical pharmacology

Dabigatran etexilate is an orally absorbed prodrug converted by esterases to dabigatran, a competitive, reversible direct inhibitor of free and fibrin-bound thrombin. It is a P-glycoprotein substrate, is not metabolised through cytochrome P450, and active dabigatran is eliminated mainly unchanged in urine; exposure and half-life rise as renal function declines. Idarucizumab is the specific reversal agent for adults when rapid reversal is required.

Formulation and product differences

• The selected product is a hard capsule that must remain intact because opening it substantially increases bioavailability.
• Capsules can be used only by patients able to swallow them whole. Other age-appropriate presentations include coated granules and powder with solvent for oral solution.
• Different formulations are not directly interchangeable without reviewing the prescription because paediatric selection depends on age, weight and swallowing ability.

Capsule

Route: Oral

Strengths: 75 mg, 110 mg, 150 mg